NDAORALCAPSULE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYNDAMAX (tafamidis) is an oral capsule medication approved by the FDA on May 3, 2019, developed by Pfizer. Data on mechanism of action and specific indications are not available in the provided dataset. The product is classified as a New Drug Application (NDA) and is currently in peak lifecycle stage.
$1.3BPart D
9.3 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions
Started Mar 2026
24 enrolled
Healthy
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Started Feb 2026
50 enrolled
Transthyretin Amyloid Cardiomyopathy
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Started Jun 2025
15 enrolled
Transthyretin Amyloid Polyneuropathy
A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults
Started Dec 2024
22 enrolled
Healthy
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
Started Jun 2024
50 enrolled
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Worked on VYNDAMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.